icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
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
Y5Hm6d7e1P8df1r5